New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
|Slideshows|June 7, 2018
- Psychiatric Times Vol 36, Issue 5
- Volume 36
- Issue 5
5 Domains of Negative Symptoms of Schizophrenia
Author(s)Dawn I. Velligan, PhD, Larry D. Alphs, PhD
Negative symptoms identified from the Negative Symptom Assessment and the behaviors that might be observed in each of 5 domains.
Advertisement
To view the 2016 article in PDF format, click here.
Articles in this issue
over 7 years ago
Introduction: Meeting Our Personal and Professional Goalsover 7 years ago
Locum Psychiatric Practice: Unexpected, Unheralded Benefitsover 7 years ago
The Role of Social Media in Private Practiceover 7 years ago
Disability: Overview of Concepts Psychiatrists Need to Knowover 7 years ago
Introduction to Immunotherapy of Malignancies for Psychiatristsover 7 years ago
Looking for AmericaAdvertisement
Related to this article
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Presenting Our November 2026 Theme: Emergency Psychiatry
2
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5